Publications

Features & Reviews

OraVerse has been featured and independently reviewed in many leading dental journals and publications.

Dental Advisor

OraVerse Product Review – Editors’ Choice, ++++ 1/2
July/August 2010

Dental Economics

Phentolamine Mesylate for the Reversal of Residual Soft-Tissue Anesthesia
Stanley F. Malamed, DDS; February 2009

Dental Products Shopper

OraVerse – Local Anesthesia Reversal Agent – Recommended Product
June 2010

Dentistry Today

Local Anesthesia Reversal
Stanley F. Malamed, DDS; March 2010

Introducing Cutting-Edge Services to Your Patients
Jose-Luis Ruiz, DDS; December 2009

Gordon Christensen’s Clinicians Report

OraVerse – The First and Only Local Anesthesia Reversal Agent
Please contact our Customer Care team at 800.872.8305 to receive a complimentary reprint of this review.

Journal of the American Dental Association

Reversal of Soft-Tissue Local Anesthesia With Phentolamine Mesylate in Adolescents and Adults
Elliot V. Hersh, DMD, MS, PhD, Paul A. Moore, DMD, PhD, MPH, Athena S. Papas, DMD, PhD, J. Max Goodson, DDS, PhD, Laura A. Navalta, BA, Siegfried Rogy, PhD, Bruce Rutherford, DDS, PhD, John A. Yagiela, DDS, PhD; AND the Soft Tissue Anesthesia Recovery Group JADA 2008; Vol 139, No 8, 1080-1093

Click here to access an abstract of this article. Please contact our Customer Care team at 800.872.8305 to receive a complimentary reprint of this article.

Reversal of Soft-Tissue Local Anesthesia With Phentolamine Mesylate in Pediatric Patients
Mary Tavares, DMD, MPH, J. Max Goodson, DDS, PhD, Deborah Studen-Pavlovich, DMD, John A. Yagiela, DDS, PhD, Laura A. Navalta, BA, Siegfried Rogy, PhD, Bruce Rutherford, DDS, PhD, Sharon Gordon, DDS, MPH, PhD, Athena S. Papas, DMD, PhD; AND Soft Tissue Anesthesia Reversal Group JADA 2008; Vol 139, No 8, 1095-1104

Click here to access an abstract of this article. Please contact our Customer Care team at 800.872.8305 to receive a complimentary reprint of this article.

What is OraVerse?

Ready. Set. Reverse!
It’s a whole new direction in
distinguishing your practice.

LEARN MORE

Safety & Efficacy

See the safety and efficacy
results from clinical trials as
well as clinical pharmacology.

LEARN MORE

Testimonials

Read what professionals from
the dental community have to
say about OraVerse.

LEARN MORE

About OraVerse

OraVerse (Phentolamine Mesylate) injection is the first and only local dental anesthesia reversal agent.

OraVerse is indicated for the reversal of soft tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. It accelerates the return to normal sensation and function following restorative and periodontal maintenance procedures. In randomized, controlled clinical trials, the median time to recovery of normal sensation in the upper lip was 50 minutes for OraVerse patients vs 133 minutes for the control and in the lower lip was 70 minutes vs 155 minutes. OraVerse is indicated for use in adults and children 6 years of age or older and weighing at least 33 lbs.

The most common adverse reaction with OraVerse is injection-site pain.

Important Safety Information

Tachycardia, bradycardia, and cardiac arrhythmias may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are uncommon with OraVerse (phentolamine mesylate), clinicians should be alert to the signs and symptoms of these events, particularly in patients with a history of cardiovascular disease. Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse, myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states.

See full prescribing information for details.